利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.04 秒)

    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING
    12.
    发明申请
    CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING 审中-公开

    公开(公告)号：US20180087069A1

    公开(公告)日：2018-03-29

    申请号：US15693558

    申请日：2017-09-01

    申请人： Oregon Health & Science University

    发明人： Louis Picker ,  Scott Hansen ,  Klaus Frueh ,  Daniel Malouli

    IPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/21 ,  A61K39/04 ,  C12N7/00 ,  A61K48/00 ,  A61K39/00

    CPC分类号： C12N15/86 ,  A61K39/04 ,  A61K39/12 ,  A61K39/21 ,  A61K48/00 ,  A61K2039/5256 ,  A61K2039/572 ,  C12N7/00 ,  C12N2710/16011 ,  C12N2710/16143 ,  C12N2740/15034

    摘要： CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.A clean version of the amended Abstract is provided below:CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL128 protein (or an ortholog thereof) but lacking an active UL130 protein (or an ortholog thereof) are provided. CMV vectors comprising a heterologous protein antigen, an active UL131 protein (or an ortholog thereof), and an active UL130 protein (or an ortholog thereof) but lacking an active UL128 protein are also provided. In addition, methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CD8+ T cells directed against epitopes presented by MHC Class II are provided.

    HIV vaccines comprising one or more population episensus antigens
    14.
    发明授权
    HIV vaccines comprising one or more population episensus antigens 有权

    公开(公告)号：US11628215B2

    公开(公告)日：2023-04-18

    申请号：US17008289

    申请日：2020-08-31

    申请人： Vir Biotechnology, Inc. ,  Triad National Security, LLC ,  Oregon Health & Science University

    发明人： Eric Bruening ,  Klaus Frueh ,  Louis Picker ,  Bette T. M. Korber ,  James Theiler ,  Emily Marshall

    IPC分类号： A61K39/21 ,  A61K39/00 ,  C12N15/86 ,  A61K39/12

    摘要： Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.

    HIV vaccines comprising one or more population episensus antigens
    16.
    发明授权
    HIV vaccines comprising one or more population episensus antigens 有权

    公开(公告)号：US10894078B2

    公开(公告)日：2021-01-19

    申请号：US15516491

    申请日：2015-10-05

    申请人： Vir Biotechnology, Inc. ,  Triad National Security, LLC ,  Oregon Health & Science University

    发明人： Eric Bruening ,  Klaus Frueh ,  Louis Picker ,  Bette T. M. Korber ,  James Theiler ,  Emily Marshall

    IPC分类号： A61K39/12 ,  C12N15/86 ,  A61K39/21 ,  A61K39/00

    摘要： Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.

    CMV VECTORS COMPRISING MICRORNA RECOGNITION ELEMENTS
    19.
    发明申请
    CMV VECTORS COMPRISING MICRORNA RECOGNITION ELEMENTS 审中-公开

    公开(公告)号：US20170143809A1

    公开(公告)日：2017-05-25

    申请号：US15356627

    申请日：2016-11-20

    申请人： OREGON HEALTH & SCIENCE UNIVERSITY

    发明人： Jay Nelson ,  Scott Hansen ,  Meaghan H. Hancock ,  Louis Picker ,  Klaus Frueh

    IPC分类号： A61K39/00

    摘要： Disclosed herein are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an active UL128 protein and an active UL130 protein. Also disclosed are recombinant CMV vectors comprising heterologous antigens and microRNA recognition elements to silence expression of CMV genes in the presence of microRNA derived from myeloid cells, an inactive UL128 protein and an inactive UL130 protein. Also disclosed are methods of generating an unconventional immune response using these vectors. Such an immune response is characterized by generation of a CD8+ T cell response that is predominantly restricted by MHC-II.